Galactosemia secondary prevention: Difference between revisions
Jump to navigation
Jump to search
| Line 7: | Line 7: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
===[[Newborn]] [[screening]]=== | ===[[Newborn]] [[screening]]=== | ||
[[Neonatal]] [[screening]] for [[galactosemia]] has already been implemented in many countries and has proven to be of benefit.<ref name="pmid12638945">{{cite journal| author=Waisbren SE, Read CY, Ampola M, Brewster TG, Demmer L, Greenstein R | display-authors=etal| title=Newborn screening compared to clinical identification of biochemical genetic disorders. | journal=J Inherit Metab Dis | year= 2002 | volume= 25 | issue= 7 | pages= 599-600 | pmid=12638945 | doi=10.1023/a:1022003726224 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12638945 }} </ref> | |||
==References== | ==References== | ||
Revision as of 10:21, 5 July 2022
|
Galactosemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Galactosemia secondary prevention On the Web |
|
American Roentgen Ray Society Images of Galactosemia secondary prevention |
|
Risk calculators and risk factors for Galactosemia secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sujaya Chattopadhyay, M.D.[2]
Overview
Secondary Prevention
Newborn screening
Neonatal screening for galactosemia has already been implemented in many countries and has proven to be of benefit.[1]
References
- ↑ Waisbren SE, Read CY, Ampola M, Brewster TG, Demmer L, Greenstein R; et al. (2002). "Newborn screening compared to clinical identification of biochemical genetic disorders". J Inherit Metab Dis. 25 (7): 599–600. doi:10.1023/a:1022003726224. PMID 12638945.